Serum HER-2/NEU decline predicts improved response to trastuzumab-based therapy (serum HER-2/NEU study group)

被引：0
|
作者：
Ali, S. M.
Esteva, F. J.
Fornier, M.
Harris, L.
Kostler, W. J.
Lotz, J. P.
Luftner, D.
Pichon, M. F.
Tse, C.
Lipton, A.
机构：
[1] Penn State Univ, Milton S Hershey Med Ctr, Lebanon VA Med Ctr, Lebanon, PA USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Mem Sloan Kettering Canc Ctr, Dept Oncol, New York, NY 10021 USA
[4] Yale Univ, New Haven, CT USA
[5] Univ Hosp Vienna, Div Oncol, Vienna, Austria
[6] Tenon Hosp, Med Oncol Serv, Paris, France
[7] Humboldt Univ, Berlin, Germany
[8] Rene Huguenin Canc Ctr, Paris, France
[9] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：69 / 69
页数：1
相关论文
共 50 条
  • [41] Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
    Mark D. Pegram
    Giovanni Pauletti
    Dennis J. Slamon
    Breast Cancer Research and Treatment, 1998, 52 : 65 - 77
  • [42] HER-2/neu as a predictive marker of response to breast cancer therapy
    Pegram, MD
    Pauletti, G
    Slamon, DJ
    BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 65 - 77
  • [43] Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Giuliani, Rosa
    Durbecq, Virginie
    Di Leo, Angelo
    Paesmans, Marianne
    Larsimont, Denis
    Leroy, Jean-Yves
    Borms, Marleen
    Vindeuoghel, Anita
    Jerusalem, Guy
    D'Hondt, Veronique
    Dirix, Luc
    Canon, Jean-Luc
    Richard, Vincent
    Cocquyt, Veronique
    Majois, Francoise
    Reginster, Michel
    Demol, Jan
    Kains, Jean-Pierre
    Delree, Paul
    Keppens, Carine
    Sotiriou, Christos
    Piccart, Martine J.
    Cardoso, Fatima
    EUROPEAN JOURNAL OF CANCER, 2007, 43 (04) : 725 - 735
  • [44] Tissue expression and serum levels of HER-2/neu in patients with breast cancer
    Krainer, M
    Brodowicz, T
    Zeillinger, R
    Wiltschke, C
    Scholten, C
    Seifert, M
    Kubista, E
    Zielinski, CC
    ONCOLOGY, 1997, 54 (06) : 475 - 481
  • [45] Expression of the HER-2/neu oncoprotein in serum in patients with renal cell carcinoma
    Rasmuson, T
    Grankvist, K
    Ljungberg, B
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 454 - 454
  • [46] Decreased survival after conversion to serum HER-2/neu positive.
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, H
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S121 - S121
  • [47] What is the role of HER-2/neu and trastuzumab (HERCEPTIN®) in lung cancer?
    Hirsch, FR
    Franklin, WA
    Bunn, PA
    LUNG CANCER, 2002, 36 (03) : 263 - 264
  • [48] Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer
    Hudelist, G
    Köstler, WJ
    Czerwenka, K
    Kubista, E
    Attems, J
    Müller, R
    Gschwantler-Kaulich, D
    Manavi, M
    Huber, I
    Hoschützky, H
    Zielinski, CC
    Singer, CF
    INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (05) : 1126 - 1134
  • [49] Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification
    Lal, P
    Salazar, PA
    Ladanyi, M
    Chen, BY
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2003, 5 (03): : 155 - 159
  • [50] Tissue expression and serum levels of HER-2/neu in patients with breast cancer
    Brodowicz, T
    Krainer, M
    Zeillinger, R
    Budinsky, AC
    Wiltschke, C
    Zielinski, CC
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 657 - 657
12345